1063 related articles for article (PubMed ID: 21031003)
1. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
Brinkmann V; Billich A; Baumruker T; Heining P; Schmouder R; Francis G; Aradhye S; Burtin P
Nat Rev Drug Discov; 2010 Nov; 9(11):883-97. PubMed ID: 21031003
[TBL] [Abstract][Full Text] [Related]
2. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Chun J; Brinkmann V
Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
4. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
5. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
Aktas O; Ingwersen J; Kieseier B; Küry P; Hohlfeld R; Hartung HP
Nervenarzt; 2011 Feb; 82(2):215-25. PubMed ID: 20842337
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod for multiple sclerosis.
Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
[TBL] [Abstract][Full Text] [Related]
7. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
8. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Gasperini C; Ruggieri S
Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA; Weinstock-Guttman B
Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod for multiple sclerosis: a review for the specialist nurse.
Harrison K
Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
13. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
14. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
15. [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
Kotov SV; Fedorova SI; Iakushina TI; Lizhdvoĭ VIu
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):74-8. PubMed ID: 23528598
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
17. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
Kipp M; Amor S
Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Chiba K; Yoshii N
Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):265-74. PubMed ID: 22728990
[No Abstract] [Full Text] [Related]
19. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
20. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
